Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infectious diseases referral hospital in Marseille, France, - January 31st to March 1st, 2020: A respiratory virus snapshot.


Journal

Travel medicine and infectious disease
ISSN: 1873-0442
Titre abrégé: Travel Med Infect Dis
Pays: Netherlands
ID NLM: 101230758

Informations de publication

Date de publication:
Historique:
received: 08 03 2020
revised: 12 03 2020
accepted: 14 03 2020
pubmed: 25 3 2020
medline: 25 9 2020
entrez: 25 3 2020
Statut: ppublish

Résumé

Rapid virological diagnosis is needed to limit the length of isolation for suspected COVID-19 cases. We managed the first 280 patients suspected to have COVID-19 through a rapid care circuit and virological diagnosis in our infectious disease reference hospital in Marseille, France. Rapid viral detection was performed on sputum and nasopharyngeal samples. Over our study period, no SARS-CoV-2 was detected. Results were obtained within approximately 3 h of the arrival of patient samples at the laboratory. Other viral infections were identified in 49% of the patients, with most common pathogens being influenza A and B viruses, rhinovirus, metapneumovirus and common coronaviruses, notably HKU1 and NL63. Early recognition of COVID-19 is critical to isolate confirmed cases and prevent further transmission. Early rule-out of COVID-19 allows public health containment measures to be adjusted by reducing the time spent in isolation.

Sections du résumé

BACKGROUND
Rapid virological diagnosis is needed to limit the length of isolation for suspected COVID-19 cases.
METHOD
We managed the first 280 patients suspected to have COVID-19 through a rapid care circuit and virological diagnosis in our infectious disease reference hospital in Marseille, France. Rapid viral detection was performed on sputum and nasopharyngeal samples.
RESULTS
Over our study period, no SARS-CoV-2 was detected. Results were obtained within approximately 3 h of the arrival of patient samples at the laboratory. Other viral infections were identified in 49% of the patients, with most common pathogens being influenza A and B viruses, rhinovirus, metapneumovirus and common coronaviruses, notably HKU1 and NL63.
CONCLUSION
Early recognition of COVID-19 is critical to isolate confirmed cases and prevent further transmission. Early rule-out of COVID-19 allows public health containment measures to be adjusted by reducing the time spent in isolation.

Identifiants

pubmed: 32205269
pii: S1477-8939(20)30100-9
doi: 10.1016/j.tmaid.2020.101632
pmc: PMC7102626
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101632

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Références

Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
Euro Surveill. 2020 Feb;25(6):
pubmed: 32070465
Travel Med Infect Dis. 2016 Jul-Aug;14(4):414-6
pubmed: 27185404
Euro Surveill. 2020 Feb;25(8):
pubmed: 32127123
N Engl J Med. 2020 Feb 27;382(9):872-874
pubmed: 31991079
Travel Med Infect Dis. 2019 Jul - Aug;30:32-38
pubmed: 30858034
Clin Infect Dis. 2017 Aug 15;65(suppl_1):S4-S11
pubmed: 28859348
J Clin Virol. 2007 Dec;40(4):333-7
pubmed: 17936066
Travel Med Infect Dis. 2019 May 3;:101410
pubmed: 31048009
Clin Chem. 2020 Apr 1;66(4):549-555
pubmed: 32031583
PLoS One. 2011;6(7):e22403
pubmed: 21811599
PLoS One. 2011 Feb 09;6(2):e16142
pubmed: 21347398
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Travel Med Infect Dis. 2020 May - Jun;35:101608
pubmed: 32114075
Travel Med Infect Dis. 2020 Jul - Aug;36:101606
pubmed: 32114074
Nat Rev Microbiol. 2019 Mar;17(3):181-192
pubmed: 30531947
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet. 2020 Mar 14;395(10227):e49-e50
pubmed: 32119824

Auteurs

Sophie Amrane (S)

IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.

Hervé Tissot-Dupont (H)

IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.

Barbara Doudier (B)

IHU-Méditerranée Infection, Marseille, France.

Carole Eldin (C)

IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.

Marie Hocquart (M)

IHU-Méditerranée Infection, Marseille, France.

Morgane Mailhe (M)

IHU-Méditerranée Infection, Marseille, France.

Pierre Dudouet (P)

IHU-Méditerranée Infection, Marseille, France.

Etienne Ormières (E)

IHU-Méditerranée Infection, Marseille, France.

Lucie Ailhaud (L)

IHU-Méditerranée Infection, Marseille, France.

Philippe Parola (P)

IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.

Jean-Christophe Lagier (JC)

IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.

Philippe Brouqui (P)

IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.

Christine Zandotti (C)

IHU-Méditerranée Infection, Marseille, France; Aix-Marseille Univ, APHM, Unité des Virus Émergents (UVE), IRD 190 - Inserm 1207, Marseille, France.

Laetitia Ninove (L)

IHU-Méditerranée Infection, Marseille, France; Aix-Marseille Univ, APHM, Unité des Virus Émergents (UVE), IRD 190 - Inserm 1207, Marseille, France.

Léa Luciani (L)

IHU-Méditerranée Infection, Marseille, France; Aix-Marseille Univ, APHM, Unité des Virus Émergents (UVE), IRD 190 - Inserm 1207, Marseille, France.

Céline Boschi (C)

IHU-Méditerranée Infection, Marseille, France.

Bernard La Scola (B)

IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.

Didier Raoult (D)

IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.

Matthieu Million (M)

IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.

Philippe Colson (P)

IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.

Philippe Gautret (P)

IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France. Electronic address: philippe.gautret@ap-hm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH